Tags

Type your tag names separated by a space and hit enter

Regular analgesic use and risk of multiple myeloma.
Leuk Res 2007; 31(4):547-51LR

Abstract

Analgesic use has been implicated in the chemoprevention of a number of solid tumors, but to date no previous research has focused on the role of analgesics in the etiology of multiple myeloma (MM). We conducted a hospital-based case-control study of 117 patients with primary, incident MM and 483 age and residence matched controls without benign or malignant neoplasms. All participants received medical services at Roswell Park Cancer Institute in Buffalo, NY, and completed a comprehensive epidemiological questionnaire. Participants who reported analgesic use at least once a week for at least 6 months were classified as regular users; individuals who did not use analgesics regularly served as the reference group throughout the analyses. We used unconditional logistic regression analyses to compute crude and adjusted odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Compared to non-users, regular aspirin users were not at reduced risk of MM (adjusted OR=0.99; 95% CI 0.65-1.49), nor were participants with the highest frequency or duration of aspirin use. A significant risk elevation was found for participants who were regular acetaminophen users (adjusted OR=2.95; 95% CI 1.72-5.08). Further, marked increases in risk of MM were noted with both greater frequency (>7 tablets weekly; adjusted OR=4.36; 95% CI 1.70-11.2) and greater duration (>10 years; adjusted OR=3.26; 95% CI 1.52-7.02) of acetaminophen use. We observed no evidence of a chemoprotective effect of aspirin on MM risk, but observed significant risk elevations with various measures of acetaminophen use. Our results warrant further investigation in population-based case-control and cohort studies and should be interpreted with caution in light of the limited sample size and biases inherent in hospital-based studies.

Authors+Show Affiliations

Department of Epidemiology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States. kristen.moysich@roswellpark.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16962170

Citation

Moysich, Kirsten B., et al. "Regular Analgesic Use and Risk of Multiple Myeloma." Leukemia Research, vol. 31, no. 4, 2007, pp. 547-51.
Moysich KB, Bonner MR, Beehler GP, et al. Regular analgesic use and risk of multiple myeloma. Leuk Res. 2007;31(4):547-51.
Moysich, K. B., Bonner, M. R., Beehler, G. P., Marshall, J. R., Menezes, R. J., Baker, J. A., ... Chanan-Khan, A. (2007). Regular analgesic use and risk of multiple myeloma. Leukemia Research, 31(4), pp. 547-51.
Moysich KB, et al. Regular Analgesic Use and Risk of Multiple Myeloma. Leuk Res. 2007;31(4):547-51. PubMed PMID: 16962170.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Regular analgesic use and risk of multiple myeloma. AU - Moysich,Kirsten B, AU - Bonner,Mathew R, AU - Beehler,Gregory P, AU - Marshall,James R, AU - Menezes,Ravi J, AU - Baker,Julie A, AU - Weiss,Joli R, AU - Chanan-Khan,Asher, Y1 - 2006/09/07/ PY - 2006/07/17/received PY - 2006/07/17/revised PY - 2006/07/29/accepted PY - 2006/9/12/pubmed PY - 2007/4/14/medline PY - 2006/9/12/entrez SP - 547 EP - 51 JF - Leukemia research JO - Leuk. Res. VL - 31 IS - 4 N2 - Analgesic use has been implicated in the chemoprevention of a number of solid tumors, but to date no previous research has focused on the role of analgesics in the etiology of multiple myeloma (MM). We conducted a hospital-based case-control study of 117 patients with primary, incident MM and 483 age and residence matched controls without benign or malignant neoplasms. All participants received medical services at Roswell Park Cancer Institute in Buffalo, NY, and completed a comprehensive epidemiological questionnaire. Participants who reported analgesic use at least once a week for at least 6 months were classified as regular users; individuals who did not use analgesics regularly served as the reference group throughout the analyses. We used unconditional logistic regression analyses to compute crude and adjusted odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Compared to non-users, regular aspirin users were not at reduced risk of MM (adjusted OR=0.99; 95% CI 0.65-1.49), nor were participants with the highest frequency or duration of aspirin use. A significant risk elevation was found for participants who were regular acetaminophen users (adjusted OR=2.95; 95% CI 1.72-5.08). Further, marked increases in risk of MM were noted with both greater frequency (>7 tablets weekly; adjusted OR=4.36; 95% CI 1.70-11.2) and greater duration (>10 years; adjusted OR=3.26; 95% CI 1.52-7.02) of acetaminophen use. We observed no evidence of a chemoprotective effect of aspirin on MM risk, but observed significant risk elevations with various measures of acetaminophen use. Our results warrant further investigation in population-based case-control and cohort studies and should be interpreted with caution in light of the limited sample size and biases inherent in hospital-based studies. SN - 0145-2126 UR - https://www.unboundmedicine.com/medline/citation/16962170/Regular_analgesic_use_and_risk_of_multiple_myeloma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0145-2126(06)00302-X DB - PRIME DP - Unbound Medicine ER -